Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01820325 |
| Title | Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer |
| Acronym | BASALT-2 |
| Recruitment | Terminated |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Novartis|Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | ITA | ESP | DEU | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | United States | Details | |
| Northwest Cancer Specialists Compass Oncology -BKM | Portland | Oregon | 97210 | United States | Details | |
| Novartis Investigative Site | Toronto | Ontario | M5G 1Z6 | Canada | Details | |
| Novartis Investigative Site | Ulm | 89081 | Germany | Details | ||
| Novartis Investigative Site | Napoli | 80131 | Italy | Details | ||
| Novartis Investigative Site | Barcelona | Catalunya | 08035 | Spain | Details | |
| Novartis Investigative Site | Madrid | 28046 | Spain | Details |